Next Article in Journal
Non-Coding RNAs in Muscle Dystrophies
Next Article in Special Issue
A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin
Previous Article in Journal
Advanced Knowledge of Three Important Classes of Grape Phenolics: Anthocyanins, Stilbenes and Flavonols
Previous Article in Special Issue
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Int. J. Mol. Sci. 2013, 14(10), 19670-19680; doi:10.3390/ijms141019670

BTG1 Expression Correlates with the Pathogenesis and Progression of Ovarian Carcinomas

1 Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China 2 Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University, Shenyang 110001, China 3 Clinical Cancer Institute, Kanagawa Cancer Center, Yokohama 241-0815, Japan
* Author to whom correspondence should be addressed.
Received: 13 May 2013 / Revised: 5 September 2013 / Accepted: 6 September 2013 / Published: 27 September 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [1265 KB, uploaded 19 June 2014]   |   Browse Figure


BTG (B-cell translocation gene) can inhibit cell proliferation, metastasis, and angiogenesis and regulate cell cycle progression and differentiation in a variety of cell types. We aimed to clarify the role of BTG1 in ovarian carcinogenesis and progression. A BTG1-expressing plasmid was transfected into ovarian carcinoma cells and their phenotypes and related proteins were examined. BTG1 mRNA expression was detected in ovarian normal tissue (n = 17), ovarian benign tumors (n = 12), and ovarian carcinoma (n = 64) using real-time RT-PCR. Ectopic BTG1 expression resulted in lower growth rate, high cisplatin sensitivity, G1 arrest, apoptosis, and decreased migration and invasion. Phosphoinositide 3-kinase, protein kinase B, Bcl-xL, survivin, vascular endothelial growth factor, and matrix metalloproteinase-2 mRNA and protein expression was reduced in transfectants as compared to control cells. There was higher expression of BTG1 mRNA in normal tissue than in carcinoma tissue (p = 0.001) and in benign tumors than in carcinoma tissue (p = 0.027). BTG1 mRNA expression in International Federation of Gynecology and Obstetrics (FIGO) stage I/II ovarian carcinomas was higher than that in FIGO stage III/IV ovarian carcinomas (p = 0.038). Altered BTG1 expression might play a role in the pathogenesis and progression of ovarian carcinoma by modulating proliferation, migration, invasion, the cell cycle, and apoptosis.
Keywords: ovarian carcinoma; BTG1; phenotypes; tumorigenesis; progression ovarian carcinoma; BTG1; phenotypes; tumorigenesis; progression
This is an open access article distributed under the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary material

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Zhao, Y.; Gou, W.-F.; Chen, S.; Takano, Y.; Xiu, Y.-L.; Zheng, H.-C. BTG1 Expression Correlates with the Pathogenesis and Progression of Ovarian Carcinomas. Int. J. Mol. Sci. 2013, 14, 19670-19680.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert